The novel ALK K1150dup mutation mediates resistance to frontline lorlatinib and retains sensitivity to gilteritinib

Abstract Lorlatinib, a third-generation ALK tyrosine kinase inhibitor (TKI), effectively targets most single ALK mutations in ALK-positive non-small cell lung cancer (NSCLC), while acquired resistance remains a major clinical challenge. In this study, we identified a novel ALK K1150dup mutation in a...

Cijeli opis

Bibliografski detalji

Glavni autori:	Mai Nagasaka, Francesco Facchinetti, Ludovic Bigot, Floriane Brayé, Matthew R. Groves, Juvenal Yosa, Anthonie van der Wekken, Mihaela Aldea, Benjamin Besse, David Planchard, Charles Naltet, Ryohei Katayama, Ken André Olaussen, Yohann Loriot, Luc Friboulet
Format:	Artigo
Jezik:	Inglês
Izdano:	Nature Portfolio 2026-05-01
Serija:	npj Precision Oncology
Online pristup:	https://doi.org/10.1038/s41698-026-01477-z
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!